Will the use of anabolic androgenic steroids become a significant cardiovascular risk factor in the future?
DOI:
https://doi.org/10.12775/JEHS.2023.45.01.019Keywords
anabolic-androgenic steroids, cardiovascular diseases, sport, addictionAbstract
Introduction and purpose: Cardiovascular diseases are the leading cause of mortality in many European countries. Major modifiable risk factors include dyslipidemia, hypertension, smoking and diabetes. The aim of our study is to draw attention to the possible impact of the use of anabolic androgenic steroids on increased cardiovascular risk.
Brief description of the state of knowledge: Currently, an increasing proportion of the population uses anabolic-androgenic steroids (AAS). This situation applies not only to athletes, but also to amateurs. The use of AAS may be associated with numerous complications. These include an increased risk of cardiovascular disease. The literature describes the effect of AAS use on the occurrence of dyslipidemia, insulin resistance, hypertension and metabolic syndrome. All these metabolic disorders result in increased cardiovascular risk. To prevent complications, it seems best to withdraw AAS gradually under medical supervision to minimize withdrawal effects.
Conclusion: The use of AAS may cause cardiovascular disease, but additional long-term studies are needed to prove this. It is necessary to sensitize patients and doctors to the problem of AAS abuse in society, because this issue can become a significant risk factor for cardiovascular diseases in near future.
References
Kotseva K, De Backer G, De Bacquer D, Rydén L, Hoes A, Grobbee D, Maggioni A, Marques-Vidal P, Jennings C, Abreu A, Aguiar C, Badariene J, Bruthans J, Cifkova R, Davletov K, Dilic M, Dolzhenko M, Gaita D, Gotcheva N, Hasan-Ali H, Jankowski P, Lionis C, Mancas S, Milićić D, Mirrakhimov E, Oganov R, Pogosova N, Reiner Ž, Vulić D, Wood D; EUROASPIRE V Investigators. Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 European countries. Eur J Prev Cardiol. 2021 May 8;28(4):370-379. doi: 10.1177/2047487320908698. Epub 2020 Mar 20. PMID: 33966079.
Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A, Boavida JM, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Di Angelantonio E, Franco OH, Halvorsen S, Hobbs FDR, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglu L, Tonstad S, Tsioufis KP, van Dis I, van Gelder IC, Wanner C, Williams B; ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227-3337. doi: 10.1093/eurheartj/ehab484. Erratum in: Eur Heart J. 2022 Nov 7;43(42):4468. PMID: 34458905.
Hoberman JM, Yesalis CE. The history of synthetic testosterone. Sci Am. 1995 Feb;272(2):76-81. doi: 10.1038/scientificamerican0295-76. PMID: 7817189.
Kanayama G, Pope HG Jr. History and epidemiology of anabolic androgens in athletes and non-athletes. Mol Cell Endocrinol. 2018 Mar 15;464:4-13. doi: 10.1016/j.mce.2017.02.039. Epub 2017 Mar 1. PMID: 28245998.
Bond P, Llewellyn W, Van Mol P. Anabolic androgenic steroid-induced hepatotoxicity. Med Hypotheses. 2016 Aug;93:150-3. doi: 10.1016/j.mehy.2016.06.004. Epub 2016 Jun 5. PMID: 27372877.
Bird SR, Goebel C, Burke LM, Greaves RF. Doping in sport and exercise: anabolic, ergogenic, health and clinical issues. Ann Clin Biochem. 2016 Mar;53(Pt 2):196-221. doi: 10.1177/0004563215609952. Epub 2015 Sep 17. PMID: 26384361.
World Anti-Doping Agency. What is Prohibited | World Anti-Doping Agency. https://www.wada-ama.org/en/prohibited-list
Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol. 2008 Jun;154(3):502-21. doi: 10.1038/bjp.2008.165. PMID: 18500378; PMCID: PMC2439524.
Sagoe D, Molde H, Andreassen CS, Torsheim T, Pallesen S. The global epidemiology of anabolic-androgenic steroid use: a meta-analysis and meta-regression analysis. Ann Epidemiol. 2014 May;24(5):383-98. doi: 10.1016/j.annepidem.2014.01.009. Epub 2014 Jan 30. PMID: 24582699.
Goldman AL, Pope HG, Bhasin S. The Health Threat Posed by the Hidden Epidemic of Anabolic Steroid Use and Body Image Disorders Among Young Men. J Clin Endocrinol Metab. 2019 Apr 1;104(4):1069-1074. doi: 10.1210/jc.2018-01706. PMID: 30239802.
Pope HG Jr, Wood RI, Rogol A, Nyberg F, Bowers L, Bhasin S. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev. 2014 Jun;35(3):341-75. doi: 10.1210/er.2013-1058. Epub 2013 Dec 17. PMID: 24423981; PMCID: PMC4026349.
Baggish AL, Weiner RB, Kanayama G, Hudson JI, Lu MT, Hoffmann U, Pope HG Jr. Cardiovascular Toxicity of Illicit Anabolic-Androgenic Steroid Use. Circulation. 2017 May 23;135(21):1991-2002. doi: 10.1161/CIRCULATIONAHA.116.026945. PMID: 28533317; PMCID: PMC5614517.
SEKUŁA, Michał Jakub, ŚWIERCZYŃSKA, Blanka, SMOLUCHOWSKI, Krzysztof, UNDZIAKIEWICZ, Adrian and PIECEWICZ-SZCZĘSNA, Halina. Hepatotoxicity of anabolic androgenic steroids in sport. Journal of Education, Health and Sport. Online. 15 September 2020. Vol. 10, no. 9, pp. 349-356. [Accessed 20 July 2023]. DOI 10.12775/JEHS.2020.10.09.040.
Sagris M, Antonopoulos AS, Theofilis P, Oikonomou E, Siasos G, Tsalamandris S, Antoniades C, Brilakis ES, Kaski JC, Tousoulis D. Risk factors profile of young and older patients with myocardial infarction. Cardiovasc Res. 2022 Jul 27;118(10):2281-2292. doi: 10.1093/cvr/cvab264. PMID: 34358302.
Achar S, Rostamian A, Narayan SM. Cardiac and metabolic effects of anabolic-androgenic steroid abuse on lipids, blood pressure, left ventricular dimensions, and rhythm. Am J Cardiol. 2010 Sep 15;106(6):893-901. doi: 10.1016/j.amjcard.2010.05.013. PMID: 20816133; PMCID: PMC4111565.
Nascimento JH, Medei E. Cardiac effects of anabolic steroids: hypertrophy, ischemia and electrical remodelling as potential triggers of sudden death. Mini Rev Med Chem. 2011 May;11(5):425-9. doi: 10.2174/138955711795445899. PMID: 21443509.
Ferrer M, Encabo A, Marín J, Balfagón G. Chronic treatment with the anabolic steroid, nandrolone, inhibits vasodilator responses in rabbit aorta. Eur J Pharmacol. 1994 Feb 3;252(2):233-41. doi: 10.1016/0014-2999(94)90602-5. PMID: 7908882.
Zaugg M, Jamali NZ, Lucchinetti E, Xu W, Alam M, Shafiq SA, Siddiqui MA. Anabolic-androgenic steroids induce apoptotic cell death in adult rat ventricular myocytes. J Cell Physiol. 2001 Apr;187(1):90-5. doi: 10.1002/1097-4652(2001)9999:9999<00::AID-JCP1057>3.0.CO;2-Y. PMID: 11241353.
Kai H, Muraishi A, Sugiu Y, Nishi H, Seki Y, Kuwahara F, Kimura A, Kato H, Imaizumi T. Expression of proto-oncogenes and gene mutation of sarcomeric proteins in patients with hypertrophic cardiomyopathy. Circ Res. 1998 Sep 21;83(6):594-601. doi: 10.1161/01.res.83.6.594. PMID: 9742054.
Fyksen TS, Vanberg P, Gjesdal K, von Lueder TG, Bjørnerheim R, Steine K, Atar D, Halvorsen S. Cardiovascular phenotype of long-term anabolic-androgenic steroid abusers compared with strength-trained athletes. Scand J Med Sci Sports. 2022 Aug;32(8):1170-1181. doi: 10.1111/sms.14172. Epub 2022 May 4. PMID: 35460300; PMCID: PMC9540672.
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 Jan 1;41(1):111-188. doi: 10.1093/eurheartj/ehz455. Erratum in: Eur Heart J. 2020 Nov 21;41(44):4255. PMID: 31504418.
Sader MA, Griffiths KA, McCredie RJ, Handelsman DJ, Celermajer DS. Androgenic anabolic steroids and arterial structure and function in male bodybuilders. J Am Coll Cardiol. 2001 Jan;37(1):224-30. doi: 10.1016/s0735-1097(00)01083-4. PMID: 11153743.
Hartgens F, Rietjens G, Keizer HA, Kuipers H, Wolffenbuttel BH. Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a). Br J Sports Med. 2004 Jun;38(3):253-9. doi: 10.1136/bjsm.2003.000199. PMID: 15155420; PMCID: PMC1724824.
Lane HA, Grace F, Smith JC, Morris K, Cockcroft J, Scanlon MF, Davies JS. Impaired vasoreactivity in bodybuilders using androgenic anabolic steroids. Eur J Clin Invest. 2006 Jul;36(7):483-8. doi: 10.1111/j.1365-2362.2006.01667.x. PMID: 16796605.
Urhausen A, Albers T, Kindermann W. Are the cardiac effects of anabolic steroid abuse in strength athletes reversible? Heart. 2004 May;90(5):496-501. doi: 10.1136/hrt.2003.015719. PMID: 15084541; PMCID: PMC1768225.
Rasmussen JJ, Schou M, Selmer C, Johansen ML, Gustafsson F, Frystyk J, Dela F, Faber J, Kistorp C. Insulin sensitivity in relation to fat distribution and plasma adipocytokines among abusers of anabolic androgenic steroids. Clin Endocrinol (Oxf). 2017 Sep;87(3):249-256. doi: 10.1111/cen.13372. Epub 2017 Jun 8. PMID: 28500659.
Singh AB, Hsia S, Alaupovic P, Sinha-Hikim I, Woodhouse L, Buchanan TA, Shen R, Bross R, Berman N, Bhasin S. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. J Clin Endocrinol Metab. 2002 Jan;87(1):136-43. doi: 10.1210/jcem.87.1.8172. PMID: 11788637.
Herbst KL, Amory JK, Brunzell JD, Chansky HA, Bremner WJ. Testosterone administration to men increases hepatic lipase activity and decreases HDL and LDL size in 3 wk. Am J Physiol Endocrinol Metab. 2003 Jun;284(6):E1112-8. doi: 10.1152/ajpendo.00524.2002. PMID: 12736156.
Thompson PD, Cullinane EM, Sady SP, Chenevert C, Saritelli AL, Sady MA, Herbert PN. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA. 1989 Feb 24;261(8):1165-8. PMID: 2915439.
Kuipers H, Wijnen JA, Hartgens F, Willems SM. Influence of anabolic steroids on body composition, blood pressure, lipid profile and liver functions in body builders. Int J Sports Med. 1991 Aug;12(4):413-8. doi: 10.1055/s-2007-1024704. PMID: 1917227.
Lenders JW, Demacker PN, Vos JA, Jansen PL, Hoitsma AJ, van 't Laar A, Thien T. Deleterious effects of anabolic steroids on serum lipoproteins, blood pressure, and liver function in amateur body builders. Int J Sports Med. 1988 Feb;9(1):19-23. doi: 10.1055/s-2007-1024972. PMID: 3366514.
LI, M.; RABKIN, S. W. Extremely low HDL cholesterol and increased LDL cholesterol induced by the use of anabolic steroids in a body builder: A case study. Int J Sports Exerc Med, 2018, 4.4: 109
Holmäng A, Björntorp P. The effects of testosterone on insulin sensitivity in male rats. Acta Physiol Scand. 1992 Dec;146(4):505-10. doi: 10.1111/j.1748-1716.1992.tb09452.x. PMID: 1492567.
Frankenfeld SP, de Oliveira LP, Ignacio DL, Coelho RG, Mattos MN, Ferreira AC, Carvalho DP, Fortunato RS. Nandrolone decanoate inhibits gluconeogenesis and decreases fasting glucose in Wistar male rats. J Endocrinol. 2014 Jan 8;220(2):143-53. doi: 10.1530/JOE-13-0259. PMID: 24403377.
Hobbs CJ, Jones RE, Plymate SR. Nandrolone, a 19-nortestosterone, enhances insulin-independent glucose uptake in normal men. J Clin Endocrinol Metab. 1996 Apr;81(4):1582-5. doi: 10.1210/jcem.81.4.8636371. PMID: 8636371.
Cohen JC, Hickman R. Insulin resistance and diminished glucose tolerance in powerlifters ingesting anabolic steroids. J Clin Endocrinol Metab. 1987 May;64(5):960-3. doi: 10.1210/jcem-64-5-960. PMID: 3549761.
Zang H, Carlström K, Arner P, Hirschberg AL. Effects of treatment with testosterone alone or in combination with estrogen on insulin sensitivity in postmenopausal women. Fertil Steril. 2006 Jul;86(1):136-44. doi: 10.1016/j.fertnstert.2005.12.039. Epub 2006 Jun 5. PMID: 16750207.
Kelly DM, Jones TH. Testosterone: a metabolic hormone in health and disease. J Endocrinol. 2013 Apr 29;217(3):R25-45. doi: 10.1530/JOE-12-0455. PMID: 23378050.
Kanayama G, Hudson JI, DeLuca J, Isaacs S, Baggish A, Weiner R, Bhasin S, Pope HG Jr. Prolonged hypogonadism in males following withdrawal from anabolic-androgenic steroids: an under-recognized problem. Addiction. 2015 May;110(5):823-31. doi: 10.1111/add.12850. Epub 2015 Feb 25. PMID: 25598171; PMCID: PMC4398624.
Yoon MS, Choi CS. The role of amino acid-induced mammalian target of rapamycin complex 1(mTORC1) signaling in insulin resistance. Exp Mol Med. 2016 Jan 8;48(1):e201. doi: 10.1038/emm.2015.93. PMID: 27534530; PMCID: PMC4686696.
Root-Bernstein R, Podufaly A, Dillon PF. Estradiol Binds to Insulin and Insulin Receptor Decreasing Insulin Binding in vitro. Front Endocrinol (Lausanne). 2014 Jul 21;5:118. doi: 10.3389/fendo.2014.00118. PMID: 25101056; PMCID: PMC4104309.
Preis SR, Massaro JM, Robins SJ, Hoffmann U, Vasan RS, Irlbeck T, Meigs JB, Sutherland P, D'Agostino RB Sr, O'Donnell CJ, Fox CS. Abdominal subcutaneous and visceral adipose tissue and insulin resistance in the Framingham heart study. Obesity (Silver Spring). 2010 Nov;18(11):2191-8. doi: 10.1038/oby.2010.59. Epub 2010 Mar 25. PMID: 20339361; PMCID: PMC3033570.
McLaughlin T, Lamendola C, Liu A, Abbasi F. Preferential fat deposition in subcutaneous versus visceral depots is associated with insulin sensitivity. J Clin Endocrinol Metab. 2011 Nov;96(11):E1756-60. doi: 10.1210/jc.2011-0615. Epub 2011 Aug 24. PMID: 21865361; PMCID: PMC3205890.
Park HS, Park JY, Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6. Diabetes Res Clin Pract. 2005 Jul;69(1):29-35. doi: 10.1016/j.diabres.2004.11.007. Epub 2004 Dec 30. PMID: 15955385.
Lee CM, Huxley RR, Wildman RP, Woodward M. Indices of abdominal obesity are better discriminators of cardiovascular risk factors than BMI: a meta-analysis. J Clin Epidemiol. 2008 Jul;61(7):646-53. doi: 10.1016/j.jclinepi.2007.08.012. Epub 2008 Mar 21. PMID: 18359190.
Sperling LS, Mechanick JI, Neeland IJ, Herrick CJ, Després JP, Ndumele CE, Vijayaraghavan K, Handelsman Y, Puckrein GA, Araneta MR, Blum QK, Collins KK, Cook S, Dhurandhar NV, Dixon DL, Egan BM, Ferdinand DP, Herman LM, Hessen SE, Jacobson TA, Pate RR, Ratner RE, Brinton EA, Forker AD, Ritzenthaler LL, Grundy SM. The CardioMetabolic Health Alliance: Working Toward a New Care Model for the Metabolic Syndrome. J Am Coll Cardiol. 2015 Sep 1;66(9):1050-67. doi: 10.1016/j.jacc.2015.06.1328. PMID: 26314534.
Xu J, Shi GP. Vascular wall extracellular matrix proteins and vascular diseases. Biochim Biophys Acta. 2014 Nov;1842(11):2106-2119. doi: 10.1016/j.bbadis.2014.07.008. Epub 2014 Jul 18. PMID: 25045854; PMCID: PMC4188798.
Petrie JR, Guzik TJ, Touyz RM. Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. Can J Cardiol. 2018 May;34(5):575-584. doi: 10.1016/j.cjca.2017.12.005. Epub 2017 Dec 11. PMID: 29459239; PMCID: PMC5953551.
Rasmussen JJ, Schou M, Madsen PL, Selmer C, Johansen ML, Hovind P, Ulriksen PS, Faber J, Gustafsson F, Kistorp C. Increased blood pressure and aortic stiffness among abusers of anabolic androgenic steroids: potential effect of suppressed natriuretic peptides in plasma? J Hypertens. 2018 Feb;36(2):277-285. doi: 10.1097/HJH.0000000000001546. PMID: 28863033.
D'Andrea A, Radmilovic J, Caselli S, Carbone A, Scarafile R, Sperlongano S, Tocci G, Formisano T, Martone F, Liccardo B, D'Alto M, Bossone E, Galderisi M, Golino P. Left atrial myocardial dysfunction after chronic abuse of anabolic androgenic steroids: a speckle tracking echocardiography analysis. Int J Cardiovasc Imaging. 2018 Oct;34(10):1549-1559. doi: 10.1007/s10554-018-1370-9. Erratum in: Int J Cardiovasc Imaging. 2018 Jul 17;: PMID: 29790034.
Calzada L, Torres-Calleja J, Martinez JM, Pedrón N. Measurement of androgen and estrogen receptors in breast tissue from subjects with anabolic steroid-dependent gynecomastia. Life Sci. 2001 Aug 17;69(13):1465-9. doi: 10.1016/s0024-3205(01)01227-9. PMID: 11554608.
Tan RS, Scally MC. Anabolic steroid-induced hypogonadism--towards a unified hypothesis of anabolic steroid action. Med Hypotheses. 2009 Jun;72(6):723-8. doi: 10.1016/j.mehy.2008.12.042. Epub 2009 Feb 23. PMID: 19231088.
Rahnema CD, Lipshultz LI, Crosnoe LE, Kovac JR, Kim ED. Anabolic steroid-induced hypogonadism: diagnosis and treatment. Fertil Steril. 2014 May;101(5):1271-9. doi: 10.1016/j.fertnstert.2014.02.002. Epub 2014 Mar 14. PMID: 24636400.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Piotr Pawłucki, Anna Maciak, Ewelina Andrasz, Paulina Cuper, Michał Sekuła, Błażej Dziurowicz
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 298
Number of citations: 0